Treatment with CIS and EQ alone or in combination showed a significant increase in hepatic total protein (p ≤ 0.01) (p ≤ 0.0001) (p ≤ 0.0001), catalase (p ≤ 0.0001), TAC (p ≤ 0.0001), and GST (p ≤ 0.01) (p ≤ 0.0001) (p ≤ 0.0001), respectively, and showed a significant decrease in hepatic MDA (p ≤ 0.0001) as compared to the EAC group (Table 4). This evidence concerns the gene CAT and in situ carcinoma.